Physician profile
David E Westerman
NPI 1689754699
$482.48
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $52.53 · 2021: $23.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $152.20 | 2019 | |
| Jazz Pharmaceuticals INC. | $63.39 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $59.63 | 2019-2020 | |
| Harmony Biosciences LLC | $44.49 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $43.43 | 2019 | |
| Mylan Specialty L.P. | $40.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.01 | 2019 | |
| Grifols USA, LLC | $31.73 | 2019 | |
| Circassia INC. | $15.31 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Westerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.